All Stories

  1. Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)

    Article • Journal of Chemotherapy, May 2019, Taylor & Francis

    Dr. Mariana Castanheira, Helio S Sader

  2. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates

    Article • Journal of Clinical Microbiology, September 2018, ASM Journals

    Helio S Sader

  3. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program

    Article • Antimicrobial Agents and Chemotherapy, September 2018, ASM Journals

    Helio S Sader

  4. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

    Article • Infection and Drug Resistance, September 2018, Dove Medical Press

    Helio S Sader, David Greenberg, Dr. Mariana Castanheira

  5. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity

    Article • Journal of Chemotherapy, July 2018, Taylor & Francis

    Helio S Sader, Dr. Mariana Castanheira

  6. Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China

    Article • Antimicrobial Agents and Chemotherapy, April 2018, ASM Journals

    Helio S Sader

  7. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

    Article • Journal of Clinical Microbiology, March 2018, ASM Journals

    Helio S Sader

  8. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

    Article • Antimicrobial Agents and Chemotherapy, December 2017, ASM Journals

    Helio S Sader

  9. In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)

    Article • Antimicrobial Agents and Chemotherapy, November 2017, ASM Journals

    Helio S Sader

  10. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates

    Article • Antimicrobial Agents and Chemotherapy, October 2017, ASM Journals

    Helio S Sader

  11. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016

    Article • Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals

    Helio S Sader

  12. Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016

    Article • Antimicrobial Agents and Chemotherapy, June 2017, ASM Journals

    Helio S Sader

  13. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015

    Article • Antimicrobial Agents and Chemotherapy, February 2017, ASM Journals

    Helio S Sader

  14. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014

    Article • Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals

    Helio S Sader

  15. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015

    Article • Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals

    Helio S Sader

  16. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States

    Article • Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals

    Helio S Sader

  17. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014

    Article • Antimicrobial Agents and Chemotherapy, April 2016, ASM Journals

    Helio S Sader, Dr. Mariana Castanheira

  18. Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014

    Article • Antimicrobial Agents and Chemotherapy, February 2016, ASM Journals

    Helio S Sader

  19. Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

    Article • Antimicrobial Agents and Chemotherapy, April 2015, ASM Journals

    Helio S Sader, Dr. Mariana Castanheira

  20. Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia

    Article • Antimicrobial Agents and Chemotherapy, March 2015, ASM Journals

    Helio S Sader

  21. Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program

    Article • Antimicrobial Agents and Chemotherapy, February 2015, ASM Journals

    Helio S Sader

  22. Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012)

    Article • Antimicrobial Agents and Chemotherapy, February 2014, ASM Journals

    Helio S Sader

  23. Post-β-Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum-β-Lactamase-Producing Strains

    Article • Antimicrobial Agents and Chemotherapy, January 2014, ASM Journals

    Helio S Sader

  24. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012

    Article • Antimicrobial Agents and Chemotherapy, December 2013, ASM Journals

    Helio S Sader

  25. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011)

    Article • Journal of Chemotherapy, December 2013, Taylor & Francis

    Helio S Sader

  26. Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Helio S Sader

  27. Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011

    Article • Antimicrobial Agents and Chemotherapy, April 2013, ASM Journals

    Helio S Sader

  28. Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011

    Article • Antimicrobial Agents and Chemotherapy, February 2013, ASM Journals

    Helio S Sader